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Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which 
the preferred treatment for localized disease is wide surgical resection. Medical manage-
ment is to a great extent undefined, and therefore for patients with regional and distal 
metastases, the development of targeted therapies is greatly desired. In this review, we 
will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and 
others) with respect to targeted therapeutic opportunities. We will also examine the role 
of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local 
and disseminated disease. Toward building a consortium of pharmaceutical, academic, 
and non-profit collaborators, we will discuss the state of resources for investigating ES 
with respect to cell line resources, tissue banks, and registries so that a roadmap can be 
developed toward effective biology-driven therapies.
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introduction
Epithelioid sarcoma (ES), first described by Enzinger over half a century ago (1), is a rare neo-
plasm accounting for <1% of adult soft tissue sarcomas and between 4 and 8% of pediatric non-
rhabdomyosarcomatous sarcomas (2, 3). ES is presumed to be a mesenchymal malignancy, but 
ES characteristically exhibits both mesenchymal and epithelial markers. The cell of origin and 
molecular drivers are still a matter of debate. ES is divided into two recognizable clinicopathologi-
cal entities, classic ES (also called distal-type ES), and proximal-type ES (Figures 1A–E). These two 
subtypes are thought be a continuum of disease rather than distinct entities (4). Distal-type ES is 
histologically identifiable by tumor nodules with central necrosis surrounded by large polygonal 
cells and spindle cells merging in the periphery (5) (Figures 1A,B). Described variants include 
angiomatoid variant, fibroma-like variant, and myxoid variant. Proximal-type ES is character-
ized by a multinodular pattern and sheet-like growth of large polygonal cells, often accompanied 
by a focal or predominant rhabdoid morphology (6) (Figures 1C,D). A specific marker has not 
yet been identified in ES. On immunohistochemistry (IHC), virtually all cases are positive for 
cytokeratin (CK) and epithelial membrane antigen (EMA) and most cases co-express vimentin. 
The marker CD34 is expressed in 60–70% of cases. IHC studies are typically negative for S-100, 
neurofilament protein, carcinoembryonic antigen, factor VIII-related antigen and CD-31, and 
INI-1 (SMARCB1) whose expression is lost in tumor nuclei (7). Establishing a diagnosis of ES can 
be difficult as tumors can present with a wide range of appearances and immunophenotypes. The 
differential diagnosis include fibrous histiocytoma, nodular fasciitis, other reactive proliferations, 
fibromatosis, giant cell tumor of tendon sheath, sclerosing epithelioid fibrosarcoma, and even 
some carcinomas and melanomas (7). IHC is helpful in differentiating these entities. Epithelioid 
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vascular tumors can resemble ES and efforts must be made 
to exclude a diagnosis of epithelioid hemangioendothelioma. 
In epithelioid hemangioendothelioma, the unique transloca-
tion t(1;3)(p36;q25), resulting in the fusion of WWTR1 with 
CAMTA1I establishes a firm diagnosis (8).
The reported overall peak incidence of ES is around 35 years of 
age (9, 10). Distal-type ES is more frequently diagnosed and tends 
to affect a younger (20–40 years of age) and more predominantly 
male population compared to proximal-type ES, which is usually 
found in an older population (20–65 years of age) (9, 11). Distal-
type ES can present itself as superficial, slow growing painless firm 
FiGURe 1 | (A,B) Distal-type ES. (A) Low power histology shows a nodule of 
tumor present in the dermis and subcutis, comprising a large area of central 
geographic necrosis, surrounded by sheets of relatively uniform polygonal 
neoplastic cells (hematoxylin and eosin, ×40). Scale bar, 500 μM. (B) At higher 
power, these are medium-sized, rounded cells, with ovoid vesicular nuclei with 
even chromatin, and small nucleoli. This example is cellular, but more sparsely 
cellular neoplasms can appear subtle, and the neoplastic cells may be 
confused with inflammatory cells. The characteristic necrosis is seen abutting 
the tumor cells (bottom left of field) (hematoxylin and eosin, ×200). Scale bar, 
50 μM. (C,D) Proximal-type ES. (C) At low power, proximal-type ES comprises 
sheets or lobules of medium-sized to large round cells, and is seen to lack the 
more defined architecture and geographic central necrosis of the distal-type 
variant (hematoxylin and eosin, ×40). Scale bar, 20 μM. (D) At higher power, this 
is characterized by a sheet-like growth of large polygonal cells, often with focal 
rhabdoid morphology, and which have ovoid vesicular nuclei, prominent large 
nucleoli, and relatively abundant eosinophilic cytoplasm. The cells are often 
more pleomorphic than those of the distal-type variant. On morphology alone, 
these cells are difficult to distinguish from other malignant epithelioid cells, such 
as those of carcinoma, melanoma, rhabdomyosarcoma, or epithelioid 
angiosarcoma, and therefore immunohistochemistry is crucial for establishing a 
correct diagnosis (hematoxylin and eosin, ×200). Scale bar, 50 μM. (e) 
Distributions of ES subytpes, adapted from the largest series reported by the 
French Sarcoma Group (9). (F) Vulnerabilities in the misassembled SWI\SNF 
complex when SMARCB1 is absent. Using epithelioid sarcoma as well as 
rhabdoid tumor as a basis for this model of SMARCB1 null tumors, the 
misassembled SWI/SNF complex has the potential to dysregulate target loci 
that may be co-regulated by other transcription factors (36, 38–40, 43) and 
thereby present indirect ways to drug target the misassembled complex.
nodules leading to chronic non-healing ulcers affecting mostly the 
hands and arms. Distal-type ES can also arise as deep-seated slow 
growing tumors in the extremities or in the tenosynovial tissues. 
Proximal-type ES is more often diagnosed as deep infiltrating soft 
tissue masses affecting axial proximal regions and is thought to be 
associated with a more aggressive course (6). Figure 1E illustrates 
the sites of involvement of disease. In the largest reported cohort, a 
majority of ES patients (47%) had localized disease at presentation 
(2). ES is one of the rare sarcomas that regularly spread to lymph 
nodes (2, 12, 13). The course of disease is characterized by mul-
tiple local recurrences and eventual metastatic spread in 30–50% 
TABLe 1 | Potential actionable biomarkers in clinical epithelioid sarcoma samples.
Biomarker Clinical relevance and incidence of biomarker Available/potential 
diagnostic
Reference
p53 84% moderate-high nuclear expression by IHC IHC via TMA (73)
Cyclin D1 96% expression by IHC IHC, FISH (89)
0% amplification by FISH
EGFR 77%-93% expression by IHC; absence of  
amplification via FISH; absence of mutation by PCR
IHC, FISH, PCR (59, 66)
VEGF-A 73% by IHC IHC via TMA (73)
VEGF-C 96% by IHC IHC via TMA (73)
mTOR (via p4EBP1 and pSRP) 100% expression by IHC via TMA IHC via TMA (59)
PTEN Loss of expression in 40% by IHC via TMA IHC via TMA (59)
β-Catenin 31% nuclear expression by IHC; 81% cytoplasmic  
expression by IHC
IHC via TMA (73)
Interleukin2-Rβ 86% expression by IHC IHC (90)
SMARCB1 (INI1) Lost expression in 85–93% by IHC; 21% mutation  
by PCR
IHC, FISH, PCR (9, 49, 50, 91, 92)
SALL4 Expression in 24% of proximal-type by IHC IHC (93)
ERG Expression in 38–68% by IHC; no found rearrangement by FISH IHC, FISH (93–95)
FLI1 95% expression by IHC IHC (94)
PBRM1 Lost expression in 83% by IHC IHC (96)
GLUT1 Expression in 50% by IHC IHC (91)
NRAS Mutated in one case report by sequence assay Sequence assay (97)
Dysadherin 54% expression by IHC IHC (70)
E-cadherin Absent expression IHC via TMA (70, 73)
SYT-SSX1 Low expression by RT-PCR in one patient; negative by FISH RT-PCR (98)
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of cases with the lungs being the primary site of involvement (11). 
It might be said that local recurrence is the gateway to metastasis.
Management and Prognosis
Optimal management of this rare sarcoma remains to be defined. 
The cornerstone of treatment of localized disease is wide surgical 
resection (14). Neo-adjuvant or adjuvant radiation therapy is often 
administered in an attempt to reduce local relapses (15, 16). The 
role of adjuvant chemotherapy is unclear (13, 14, 17, 18). Despite 
multimodal management, the relapse rate remains high and recur-
rences tend to occur many years later following initial therapy. 
Reported local relapse rates are ~35% (11, 18, 19). Patients with 
localized disease fare better compared to regional disease [5-year 
overall survival (OS) of 75 vs. 49%]. Pediatric patients seem to 
have a favorable prognosis [5-year OS of 92.4%] as they are more 
likely to be diagnosed with localized distal-type ES and are less 
likely to have nodal or metastatic involvement at presentation (3).
Even though reasonable control of localized disease is possible, 
metastatic spread is seen in approximately half of patients (2). The 
available literature on palliative chemotherapy in ES is limited to 
case reports and small retrospectives studies. The most commonly 
administered chemotherapy regimens are single-agent anthracy-
cline therapy or the combination an anthracycline with ifosfamide 
(20). A single group reported activity of a regimen combining 
gemcitabine with docetaxel, but the experience is limited to a small 
number of patients (21). The activity of navelbine was raised in 
a case report and may warrant further investigation (22). Partial 
responses are rare. Most patients achieve stable disease at best with 
palliative chemotherapy. In one study, tumor regression was only 
seen in distal-type disease (20). However, another group reported 
high-response rates in proximal-type ES using doxorubicin-ifosfa-
mide combination (23). With the medical evidence being limited to 
small retrospectives studies, it is difficult to draw definitive conclu-
sions regarding the chemosensitivity of this histological subtype.
Despite the administration of palliative chemotherapy, patients 
with metastasis have a poor prognosis. The reported median sur-
vival is ~52 weeks and the 1- and 5-year survival rates are 46 and 
0%, respectively (2, 20). Therefore, a substantial unmet need exists 
to improve the medical management of ES patients by establishing 
novel systemic regimens and exploring novel targeted therapy. In 
this review, we will summarize our current understanding of the 
underlying biology of this rare disease by highlighting implicated 
signaling pathways and potential actionable biomarkers (Table 1). 
In order to establish a roadmap that can be developed toward 
effective biology-driven therapies, we will highlight therapeutics 
opportunities and drugs with promising activity.
Cytogenetic Analyses
Cytogenetic analyses were first attempted to better understand 
the biology of ES (24–29). The karyotype analysis on clinical 
TABLe 2 | epithelioid sarcoma potential targets and corresponding 
experimental model systems.
Biomarker Human cell line(s) Reference
ALK YCUS-5 (31)
AKT VAESBJ, Epi544 (58, 59)
c-MET ASRA-EPS, VAESBJ (58)
Dysadherin HS-ES-1M, YCUS-5, 
ES-OMC-MN, SFT-8606
(70)
EGFR VAESBJ, Epi544, GRU-1 (59, 99)
HGFR/MET VAESBJ (44)
IL-6 and IL-6R ES-OMC-MN (100)
LRP ES-OMC-MN, SFT-8606 (85)
Metal free protoporphyrin IX Va-es-bj (101)
MMP-2, MMP-9, TIMP-1,  
TIMP-2, TIMP-4
GRU-1 (59, 102)
MUC gene FU-EPS-1, SFT-8606 (80)
mTOR VAESBJ, Epi544 (59)
PDGF GRU-1 (99)
RAR-α, RAR-β, and RAR-γ GRU-1 (103)
TGF-α GRU-1 (99)
TGF-β/Smad signaling and  
CD 109
ESX (99, 104)
TNF receptors GRU-1 (103)
Tyrosine hydroxylase gene (TH) YCUS-5 (31)
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samples or cells lines varied greatly and was mostly done in adult 
cases. A minority of samples were diploid, some polypoid, while 
a great majority had complex patterns consisting of multiple 
numerical and structural rearrangements (see Table 3). Pediatric 
cytogenetic analyses seem to indicate less complex genetic altera-
tions compared to adults and may therefore offer an explanation 
of their more favorable prognosis (30, 31). Translocations t(8;22)
(q22;q11) in distal-type ES and t(10;22) in proximal-type ES were 
found (24, 32). However, compared to other translocation-driven 
sarcomas, there is no unique identifiable reoccurring cytogenetic 
pattern in ES. The only identified recurrent breakpoints have 
been structural rearrangements involving 18q11 and 22q11. The 
observation that a substantial number of ES had either rearrange-
ments or deletions of 22q led to the hypothesis that this region 
may contain a tumor suppressor gene (32, 33). Further studies 
identified SMARCB1 as being involved in the tumorigenesis of 
ES (34).
SMARCB1
The SMARCB1 gene, located at 22q11, codes for BAF47, a core 
subunit of the SWI/SNF ATP-dependent chromatin remodeling 
complex and acts as a tumor suppressor gene (35). Components 
of the SWI/SNF complex are mutated in 20% of cancers, most 
notably rhabdoid tumor (36). This complex regulates genes 
by enabling the nucleosome to reposition itself in relation to 
the DNA sequence (37). Inactivation of SMARCB1 leads to 
neoplastic transformation by transcriptional deregulation of 
target genes implicated in regulating genomic stability, cell-cycle 
progression, and other signaling pathways in cooperation with 
transcriptional co-regulators (e.g., MyoD, Olig2) (36, 38, 39). 
SMARCB1 was shown to transcriptionally regulate p16INK4a 
and/or p21 and repress cyclin D1, thereby suppressing E2F 
activity and its target genes (40–42). SMARCB1-deficient cells 
have been implicated to have aberrant Hedgehog signaling path-
way activation (40, 43). Brenca et al. demonstrated that loss of 
SMARCB1 expression in the ES cell line VAESBJ was caused by 
homozygous deletion of SMARCB1 through mutations of exon 
1. They also identified equally prevalent homozygous deletion 
of CDKN2A and CDKN2B loci, responsible for encoding p16, 
p14, and p15 proteins. Restoration of SMARCB1 led to a reduc-
tion of cell proliferation and cell migration and to an increase 
in sensitivity to genotoxic stress, thereby providing evidence 
to support SMARCB1 inactivation in the tumorigenesis of ES 
(44). For rhabdoid tumor, SWI/SNF disruption is sufficient to 
cause neoplastic transformation (45). However, in the context 
of ES, loss of SMARCB1 by itself is not sufficient. Interestingly, 
knockout of SMARCB1 in primary fibroblast cells causes rapid 
growth arrest and p53-mediated programed cell death (46). 
However, when mutations of TP53 co-exist, tumor proliferation 
is dramatically increased (47). Brenca et al. demonstrated that 
the VAESBJ cell line retains wild-type TP53, but hypothesized 
that the homozygous loss of CDKN2A which leads to impaired 
p16/RB and p14/TP53 responses likely contributes to the 
genomic instability seen in this cell line (44). Hence, other 
signaling pathways may contribute to tumor progression in 
ES as witnessed by the complex genetic landscape reported in 
cytogenetic studies. Whether the SMARCB1-deficient SWI/SNF 
complex exists in a misassembled state as it does in rhabdoid 
tumor (48), and to what extent the misassembled complex aber-
rantly deregulates loci that are not normally associated with the 
SWI/SNF complex remains to be investigated. Most certainly, 
the milieu of transcriptional co-regulators in ES will be different 
than in rhabdoid tumor.
Targeting SMARCB1 is complicated by the different mecha-
nisms of loss of expression. IHC studies demonstrated that the 
loss of expression of SMARCB1 ranges from 85 to 93% of cases 
(9, 34, 49, 50). Allelic homozygous deletions varied from 5 to 
71%; however, the true value may be ~10% (51–53). Papp et al. 
identified different mechanisms to explain the loss of expression 
of SMARCB1: 13% of cases had biallelic deletions, 33% showed 
single-allelic deletion, and 4% had point mutations (52). In 59% of 
cases, both alleles were intact and no cases had promoter hyper-
methylation nor post-translational modification. The authors 
went on to show that loss of SMARCB1 protein expression in those 
cases is due to epigenetic gene silencing by oncomiRs. Three of 
the overexpressed miRNAs (miR-206, miR-381, and miR-671-5p) 
could silence the SMARCB1 mRNA expression in cell cultures 
(54). The role of oncomiRs was also validated by another group 
where miR193a-5p could equally inhibit the mRNA expression 
of SMARCB1 (55). Beyond targeting the misassembled SWI/SNF 
complex, transcriptional co-regulators are also theoretical targets 
(Figure 1F). In summary, loss of SMARCB1 has a crucial role in 
the pathogenesis of ES (along with other signaling pathways) and 
therefore is an interesting target to pursue for the development of 
new therapies. Acknowledging that the restoration of SMARCB1 
function is likely the primary therapeutic opportunity in ES, in the 
paragraphs to follow we discuss other therapeutic opportunities 
TABLe 3 | Demographic and biological features of human epithelioid sarcoma cell lines.
Cell line 
name
Histology Age 
(years)
Sex Primary 
site
Metastatic Cell line 
source
Select chromosomal marker(s) Mutation(s) Primary 
reference 
(PMiD or 
other)
Related 
references 
(PMiD or 
other)
Originating investigator 
(and institution) or 
commercial source(s)
Reference
RM-HS1 37 M Left foot 2432306 Reeves (105)
HX 165 c 28 M Penile Local 
recurrence
3179184 Kelland (Institute of Cancer 
Research, UK)
(106)
GRU-I 32 F Left 
buttock
Yes Para-iliac 
lymph-node
1688830 7525493 Gerharz (University of 
Mainz)
(107)
SARCCR 2 33 F Knee Local 
recurrence
Chromosomes 13, 14, 16, 18, and 22 
were deleted in all cells
8099901 Roché (Centre Claudius 
Regaud)
(83)
HS-ES-1M Proximal-
type
60 M Right 
perineum 
nodule
Yes Local 
recurrence
All exhibited the identical abnormal 
karyotype of 46, XY, 1i(8)(q10),221, 
del(22)(q12)
9216728 Sonobe (Kochi Medical 
School)
(28)
ES020488 26 M Yes Cutaneous 
metastasis
39–83 chromosomes, with various 
abnormalities but no specific pattern
7685133 Sonobe (Kochi Medical 
School, Japan)
(108)
Va-es-bj 41 M Epidural 
tumor
Yes Bone 
marrow 
aspirate
Chromosomal triploidy with marker 
chromosomes
21552805 8572585 Helson (St Agnes Hospital) (109)
ES-OMC-
MN
Distal-type 44 F Right leg 
nodule
Yes Chest wall Modal chromosome number was 
45, X, in 74% of metaphases. Other 
chromosome numbers were 47, XXX, 
in 14% of metaphases, and 46, XX, in 
12% of metaphases
9143739 Kusakabe (Osaka Medical 
College)
(100)
Except for a number of sex 
chromosomes, the chromosomes had 
no chromosomal anomaly
YCUS-5 Proximal-
type
3 F Neck 
mass
no Neck mass  48, XX, t(2;7)(p23;q32 ~ 34), ?del(6)
(q2?5), +7, +8
expression 
tyrosine 
hydroxylase gene 
(TH) expression 
of ALK
10398195 Goto (Yokohama City 
University School of 
Medicine)
(31)
SFT-8606 Distal-type 75 M Left 
elbow
yes Primary 
tumor
Complex numerical and structural 
aberrations, including add(8)(p23), 
add(9)(p13), der(12)t(12;14)(p13;q22), 
+i(21)(q10), der(22)t(18;22)(q11;p11.2)
8908166 Iwasaki (Fukuoka 
University School of 
Medicine)
(26)
Stenman 
cell line
64 M Left 
forearm
yes Axillary 
lymph node
No <14 different marker chromosomes 
were found, of which all but four 
resulted from terminal deletions
Elevated p21 
expression was 
probably due to 
an overexpression 
of the N-ras gene
2196989 Stenman (Gothenburg 
University)
(110)
Most frequent del(1) (p21-22), found in 
about 25% of the cells karyotyped
(Continued)
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TABLe 3 | Continued
Cell line 
name
Histology Age 
(years)
Sex Primary 
site
Metastatic Cell line 
source
Select chromosomal marker(s) Mutation(s) Primary 
reference 
(PMiD or 
other)
Related 
references 
(PMiD or 
other)
Originating investigator 
(and institution) or 
commercial source(s)
Reference
FU-EPS-1 21 M Right 
upper 
arm
Yes Axillary 
node
Hyperdiploid karyotype with the 
following chromosomal abnormalities: 
+i(5)(p10), −8, +13, der(13)t(8;13)
(q?;p11), +der(19)t(9;19)(?;?), and 
del(22)(q13). Gains of 5p, 9q, 19q, and 
22q and a loss of 8p
16010416 Nishio (Fukuoka University 
Faculty of medicine)
(111)
NEPS Classical 32 M Forearm Primary 
tumor
19756736 Hoshino (Niigata University 
Graduate School of 
Medical and Dental 
Sciences)
(80)
Epi-544 Foot Modal chromosomal number of 
45 (range, 42–45), monosomy of 
chromosomes 2, 8, 13, and X, trisomy 
of chromosome 5, and the following 
structural abnormalities: del 7q, del 9q, 
del 12p, 16q, t(9q;14q), and t(2q;?)
21357725 Sakharpe (University 
of Texas MD Anderson 
Cancer Center)
(73)
ESX Proximal-
type
73 F Left thigh Yes Primary 
tumor
65 ~ 68, X, −X, or -Y, add (X)(q22), 
+1, add(1) (p32), add(1) (q21), add(1)
(q42), add(1)(q42), der(4;10)(q10;q10), 
add(8)(p11.2), −9, add(9)(p22), der(11)
t(11;14)(p13;q13), −13, add(13)(q22), 
−14, −15, add(16)(p13.1), −17, −18, 
add(18)(q21), +21, add(22)(q13), 
+4 ~ 6mar
CD109 mRNA 
expression
24376795 Emori (Sapporo Medical 
University School of 
Medicine)
(104)
Asra-EPS Angiomatoid 
ES
67 M Right 
elbow 
mass
No Primary 
tumor
Karyotype showed near-tetraploidy 
with some chromosomal translocations 
and fragments
23915498 Imura (Osaka University 
Graduate School of 
Medicine)
(112)
No recurrent chromosomal 
translocation was detected. 90, XXYY,  
−4, +5, +8, +9, −10, −13, t(13;15), 
+14, −15, −15, −20, −22, −22, 
+1mar
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related to consistent alterations in other signaling pathways that 
may also contribute to the pathogenesis of ES.
Pi3K–AKT–mTOR Signaling Pathway
The phosphatidylinositol 3-kinase/protein kinase-B/mammalian 
target of rapamycin (PI3K/AKT/mTOR) signaling pathway has 
been studied extensively and is activated in a myriad of cancers. 
This signaling pathway’s signaling regulates cell proliferation, 
differentiation, cellular metabolism, and cytoskeletal reor-
ganization leading to apoptosis and cancer cell survival (56). A 
previous study done on SMARCB1-deficient tumor cells revealed 
persistent AKT activation (57). This finding led Imura et al. to 
further investigate the importance of this signaling pathway in ES 
(58). By studying two SMARCB1-deficient cell lines (VAESBJ and 
Asra-EPS), this group has shown that AKT/mTOR pathway is 
constitutively hyperactivated. Results demonstrated that silencing 
mTOR by transfecting cell lines with anti-mTOR-specific  siRNAs 
suppressed cell proliferation. However, inhibition of mTOR 
with everolimus caused tumor growth delay without shrinkage. 
Blocking the mTOR signaling pathway with everolimus caused 
an increase in AKT and ERK activity, which was subsequently 
shown to be dependent of c-MET activation. Blocking c-MET 
activation had a variable effect on growth inhibition on studied 
cell lines. This variability could be partially explained by the degree 
of loss of PTEN, which is thought to contribute to resistance to 
c-MET inhibitors through sustained AKT activation upon mTOR 
blockade. Combining agents to block both AKT and c-MET were 
more effective in inducing tumor arrest compared to using either 
one alone. The importance of AKT and c-MET/HGF pathways 
was also highlighted through immunohistochemical analysis of 
random clinical samples. The variability of AKT activation and 
loss of PTEN expression in different cell lines were also confirmed 
by another group and thought to correlate with sensitivity of 
rapamycin (59). This heterogeneity could highlight the complex 
genetics of the disease as well as the variable importance of 
PI3K/AKT/mTOR signaling pathway in the tumorigenesis of ES. 
In vitro sensitivity to mTOR inhibitors is likely an imperfect sur-
rogate for clinical activity. Nonetheless, these preclinical data are 
interesting and may warrant additional studies before pursuing 
clinical trials. Resistance to single-agent mTOR inhibitors can 
not only be a potential issue but can also possibly be overcome 
by simultaneously targeting other pathways. These findings are 
consistent with the shortcomings of targeting mTOR signaling 
pathway in general and highlight the importance of patient selec-
tion and identification of putative biomarkers (60).
eGF Pathway
The human epidermal growth factor signaling pathway regroups 
four distinct receptor tyrosine kinases, HER1 (ErbB-1, EGFR), 
HER2 (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4) and is 
implicated in cell proliferation, apoptosis, and angiogenesis (61). 
The role of EGFR in malignant transformation of carcinomas 
has been extensively studied. Recently, EGFR expression was 
revealed to be present in soft tissue and bone sarcomas (62, 
63). However, subsets of disease demonstrating tyrosine kinase 
domain mutations were rare (64, 65). These findings sparked 
an interest in studying EGFR in ES. Cascio et  al. showed that 
93% of clinical samples (including distal and proximal-type ES) 
expressed EGFR by IHC (66). This high level of expression of 
EGFR was also corroborated by Xie et  al. (59). Furthermore, 
Cascio et al. went on to show an absence of EGFR amplification 
via FISH studies. Sequencing of the EFGR gene tyrosine kinase 
domain revealed no point mutations, insertions, or deletions. 
Xie et al. further investigated the role of EGFR pathway in the 
tumorigenesis of ES. EGF-induction contributes to cell-cycle 
progression partly through upregulation of cyclin D1. EGFR 
activation also causes an increase in migration and invasion of ES 
cells where high levels of expression of MMP2 and MMP9 were 
found. Next, this group tested whether EGFR inhibition with 
erlotinib would be a viable therapy. Exposure to erlotinib caused 
tumor growth delay without causing tumor arrest. An explana-
tion for this incomplete response is given by the cooperation of 
HGFR/MET pathway with EGFR in sustaining AKT and ERK 
phosphorylation. Dual inhibition of both those pathways had a 
synergistic effect in decreasing cell proliferation (44). Combining 
inhibition of EGFR pathway with erlotinib and mTOR pathway 
with rapamycin also proved to be synergistic causing cell-cycle 
arrest as well as an increase in apoptosis (59). Targeting solely the 
EGFR pathway may not translate to a possible clinical benefit. 
However, combined inhibition of EFGR with either mTOR or 
HGFR\MET may worth investigating further through preclinical 
animal studies.
Other Possible Actionable Pathways and 
Targets
Dysadherin is a cancer-associated cell membrane glycoprotein 
shown to downregulate E-cadherin cell-mediated adhesion 
and to promote metastasis (67). Dysadherin contributes to 
metastatic progression through autocrine activation of CCL2 
expression in part through activation of the nuclear factor-kap-
paB pathway (68). Dysadherin also has the ability to attribute 
stem-cell like properties to cancer cells (68, 69). Higher mRNA 
expression levels of dysadherin were documented in cell lines 
derived from proximal-type ES compared to distal-type ES 
(70). This difference in expression in levels of dysadherin may 
offer a possible explanation to the poor prognosis associated 
with proximal-type ES. Interestingly, in breast cancer cell lines, 
dysadherin overexpression was shown to possibly enhance AKT 
activation. Subsequently, inhibiting AKT reduced dysadherin’s 
ability to promote cell mobility and tumor cell invasion (71). 
Targeting dysadherin could be potentially exploited to treat 
ES, but further work is needed. Agonists of the CCL2 recep-
tor, CCR2, such as PF-04634817, may be one area to begin 
investigation.
The role of Wnt/β-catenin signaling pathway in cancer is well 
documented. APC deficiency or β-catenin mutations preventing 
its degradation lead to constitutive activation of β-catenin signal-
ing, which in turn contribute to stem-cell renewal and prolifera-
tion (72). In ES, IHC studies revealed low expressions of nuclear 
β-catenin (73). Furthermore, no β-catenin gene mutations were 
found (74). Therefore, the proliferative abilities of ES cells are 
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CA125 was first identified and used as a serum marker for 
epithelial ovarian carcinoma (78). IHC studies revealed high 
positivity and specificity of CA125 in ES compared to other 
sarcomas (79). High expressions of the MUC16 gene were identi-
fied by RT-PCR in ES cell lines. Serum levels of CA125 also seem 
to correlate with disease progression (80). Measuring CA125 
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Tyrosine Kinase inhibitors
As stated previously, chemotherapy has a limited role in the 
management of ES. Early studies explored the reasons underly-
ing chemotherapy resistance. A study of the SARCCR2 cell 
line showed overexpression of P-glycoprotein, an ATP-binding 
cassette (ABC) chemotherapy export pump. Using verapamil 
and cyclosporine A to reverse multidrug resistance, the authors 
showed increased sensitivity to doxorubicin and vincristine 
(83). For the GRU cell line, expression of P-glycoprotein and 
MRP could also be observed (84). However, one study identi-
fied an absence of expression of P-glycoprotein and MRP in the 
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these studies demonstrated the presence of lung resistant protein 
(LRP), which mediates multidrug resistance (MDR). Results 
showed that reversing MDR with cyclosporin A increased sensi-
tivity to actinomycin D, vincristine, and adriamycin. The use of 
tyrosine kinase inhibitors, the newest ABC inhibitors, to reverse 
multidrug resistance remains unexplored and may potentially 
enhance the efficacy of chemotherapy in ES.
The medical evidence for the utility of tyrosine kinase inhibi-
tors impacting ES is scarce. To our knowledge, only one case was 
reported in the medical literature. Sunitinib showed reasonable 
disease stabilization in a patient with metastatic ES (86). The 
underlying reasons why sunitinib was active in this patient are 
unknown and cannot be explained with what is currently known 
about the biology of this disease. Pazopanib, a recent oral tyrosine 
kinase inhibitor approved for the treatment of soft tissue sarcoma 
(87), is worth investigating prospectively as its activity is similar 
to sunitinib. Work is still needed in mapping out active signaling 
pathways and identifying actionable tyrosine kinase domain muta-
tions. Polykinase inhibitors remain therefore greatly unexplored 
in the management of ES and may one day improve outcome.
Future Perspectives
Researching and developing new treatment strategies in rare 
cancers is a challenge, but possible with technology and resources 
available today and regulatory agency incentives (88). ES is a 
perfect model to envision what personalized medicine promises 
for the future. The intent of this review was to draw a roadmap 
to develop efficient biology-driven therapy. Achieving this will 
start with the selection of representative cell lines and mouse 
models of ES (Available cell lines and potential actionable tar-
gets are summarized in Tables 2 and 3). Many of the potential 
targets highlighted in this article were based on IHC-expression 
or reverse-transcriptase PCR studies. DNA deep-sequencing 
projects may demonstrate underlying genomic amplification and 
mutations that can be targeted. Partnership with pharmaceutical 
companies would allow screening of thousands of compounds 
on selected cell lines presenting mutations or other actionable 
targets. Active drugs may then undergo preclinical testing. Those 
most promising can be prioritized for clinical trials. Drugs 
being developed in other cancers that share common signaling 
pathways aberrations with ES may also prove to be useful. It is 
possible to perform basket trials in rare cancers, and this could 
be a way of evaluating novel agents in this extremely rare disease. 
On the way of developing new therapies, possible pitfalls can be 
expected. As demonstrated on ES cell line models, targeting a 
single signaling pathway may be insufficient. The complexity of 
the genetic landscape and the crosstalk between multiple signal-
ing pathways contribute to resistance. This can be overcome 
by targeting multiple signaling pathways simultaneously. Only 
through international collaboration between pediatric and adult 
units, we can remain hopeful that targeted and immune therapy 
will have a major impact in the management of ES in the near 
future.
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